December 3, 2013
November 6, 2013
Treg: Regulatory T Cells and T Helper Cells
TxCell is developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases.
TxCell's strategy is to target niche and orphan indications for which there are few or no treatment options and a high unmet medical need.
The product candidates developed by TxCell consist of autologous antigen-specific type 1 regulatory T cells (Ag-Tregs) generated ex-vivo from patient's peripheral blood in a proprietary manufacturing process (link).
Our lead product candidate, Ovasave, has successfully completed a PI/II clinical trial in Crohn's disease patients, refractory to all current treatments, with promising results (link). The next step in this program will be an international PIIb clinical trial to confirm the positive PI/II study results.
TxCell has a unique proprietary, breakthrough technology platform, using type 1 regulatory T cells (link). New product candidates for other indications are in preclinical development.